Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Imaging surveillance in multiple endocrine neoplasia type 1 : Ten years of experience with somatostatin receptor positron emission tomography. / Said, Maha; Krogh, Jesper; Feldt-Rasmussen, Ulla; Rasmussen, Åse Krogh; Kristensen, Thomas Skaarup; Rossing, Caroline Maria; Johannesen, Helle Hjorth; Oturai, Peter; Holmager, Pernille; Kjaer, Andreas; Klose, Marianne; Langer, Seppo; Knigge, Ulrich; Andreassen, Mikkel.
In: Journal of Neuroendocrinology, Vol. 35, No. 8, e13322, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Imaging surveillance in multiple endocrine neoplasia type 1
T2 - Ten years of experience with somatostatin receptor positron emission tomography
AU - Said, Maha
AU - Krogh, Jesper
AU - Feldt-Rasmussen, Ulla
AU - Rasmussen, Åse Krogh
AU - Kristensen, Thomas Skaarup
AU - Rossing, Caroline Maria
AU - Johannesen, Helle Hjorth
AU - Oturai, Peter
AU - Holmager, Pernille
AU - Kjaer, Andreas
AU - Klose, Marianne
AU - Langer, Seppo
AU - Knigge, Ulrich
AU - Andreassen, Mikkel
N1 - © 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
PY - 2023
Y1 - 2023
N2 - Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive imaging surveillance without specifying a superior regimen, including the role of somatostatin receptor imaging (SRI) with positron emission tomography (PET). The primary outcomes were to: (1) Assess change in treatment of duodenal-pancreatic neuroendocrine neoplasms (DP-NENs), bronchopulmonary NENs, and thymic tumors attributed to use of SRI PET/computed tomography (CT) and (2) estimate radiation from imaging and risk of cancer death attributed to imaging radiation. This was a retrospective single center study, including all MEN1 patients, who had had at least one SRI PET/CT. A total of 60 patients, median age 42 (range 21-54) years, median follow-up 6 (range 1-10) years were included. Of 470 cross sectional scans (MRI, CT, SRI PET/CT), 209 were SRI PET/CT. The additional information from SRI PET had implications in 1/14 surgical interventions and 2/12 medical interventions. The estimated median radiation dose per patient was 104 (range 51-468) mSv of which PET contributed with 13 (range 5-55) mSv and CT with 91 mSv (range 46-413 mSv), corresponding to an estimated increased median risk of cancer death of 0.5% during 6 years follow-up. SRI PET had a significant impact on 3/26 decisions to intervene in 60 MEN1 patients followed for a median of 6 years with SRI PET/CT as the most frequently used modality. The surveillance program showed a high radiation dose. Multi-modality imaging strategies designed to minimize radiation exposure should be considered. Based on our findings, SRI-PET combined with CT cannot be recommended for routine surveillance in MEN1 patients.
AB - Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive imaging surveillance without specifying a superior regimen, including the role of somatostatin receptor imaging (SRI) with positron emission tomography (PET). The primary outcomes were to: (1) Assess change in treatment of duodenal-pancreatic neuroendocrine neoplasms (DP-NENs), bronchopulmonary NENs, and thymic tumors attributed to use of SRI PET/computed tomography (CT) and (2) estimate radiation from imaging and risk of cancer death attributed to imaging radiation. This was a retrospective single center study, including all MEN1 patients, who had had at least one SRI PET/CT. A total of 60 patients, median age 42 (range 21-54) years, median follow-up 6 (range 1-10) years were included. Of 470 cross sectional scans (MRI, CT, SRI PET/CT), 209 were SRI PET/CT. The additional information from SRI PET had implications in 1/14 surgical interventions and 2/12 medical interventions. The estimated median radiation dose per patient was 104 (range 51-468) mSv of which PET contributed with 13 (range 5-55) mSv and CT with 91 mSv (range 46-413 mSv), corresponding to an estimated increased median risk of cancer death of 0.5% during 6 years follow-up. SRI PET had a significant impact on 3/26 decisions to intervene in 60 MEN1 patients followed for a median of 6 years with SRI PET/CT as the most frequently used modality. The surveillance program showed a high radiation dose. Multi-modality imaging strategies designed to minimize radiation exposure should be considered. Based on our findings, SRI-PET combined with CT cannot be recommended for routine surveillance in MEN1 patients.
U2 - 10.1111/jne.13322
DO - 10.1111/jne.13322
M3 - Journal article
C2 - 37564005
VL - 35
JO - Journal of Neuroendocrinology
JF - Journal of Neuroendocrinology
SN - 0953-8194
IS - 8
M1 - e13322
ER -
ID: 363195225